CF and COVID-19: The Data and the Real World

COVID-19 Special Edition

CF and COVID-19: The Data and the Real World

In this issue:

Do cystic fibrosis lung impairment and the COVID-19 virus create the disastrous combination they would seem to make? What do the currently published data say about the clinical effects of the pandemic on people living with CF? How have the safety-mandated lockdowns and clinic closures affected CF care teams’ ability to effectively maintain their patients’ health? What information out there is proved, what’s speculation, and what is simply unknown?

These questions are the focus of this eCysticFibrosis Review Special COVID Edition issue. Lisa Saiman MD, MPH, professor of pediatrics at Columbia University Irving Medical Center, analyzes the current literature investigating these questions and then speaks directly with front-line clinicians about what they’re experiencing as they navigate a disrupted health care system.

Learning objective:

Evaluate the effects of the ongoing COVID-19 pandemic on the treatment of people with CF.

Authors:

Lisa Saiman, MD, MPH

Professor of Pediatrics
Columbia University Irving Medical Center
Hospital Epidemiologist, Department of Infection and Control
New York-Presbyterian Hospital
New York, NY

John J. LiPuma, MD

Professor of Pediatrics
University of Michigan Medical School
Director, Pediatric Infectious Diseases
C.S. Mott Children’s Hospital
Ann Arbor, MI

Robert W. Miller, MD

Pediatric Pulmonologist
Lehigh Valley Reilly Children’s Hospital
Director, Lehigh Valley Cystic Fibrosis Center
Allentown, PA

Marianne Muhlebach, MD

Professor of Pediatrics, Division of Pulmonary Medicine
University of North Carolina at Chapel Hill
Chapel Hill, NC

Guest Faculty Disclosures

Dr. Saiman has disclosed that she has served as a principal investigator for Merck & Co., Inc., and received consulting fees from AstraZeneca and MatrixAP.

Dr. LiPuma has disclosed that he has received consulting fees from Johnson and Johnson.

Dr. Miller has disclosed that he has no financial interests or relationships with a commercial entity.

Dr. Muhlebach has disclosed that she has no financial interests or relationships with a commercial entity.

Unlabeled/Unapproved Uses

The authors have indicated that there will be unlabeled/unapproved references to antiviral agents remdesivir, convalescent plasma, and steroids for the treatment of COVID-19.

Program Directors:

Noah Lechtzin, MD, MHA

Director, Adult Cystic Fibrosis Program
Associate Professor of Medicine
Johns Hopkins University School of Medicine
Baltimore, MD

Peter J. Mogayzel, Jr., MD, PhD

Professor of Pediatrics
Director, Cystic Fibrosis Center
Johns Hopkins University School of Medicine
Baltimore, MD

Donna Peeler, RN

Clinical Nurse
Pediatric Clinic Coordinator
Johns Hopkins Cystic Fibrosis Center
Baltimore, MD

Guest Faculty Disclosures:

Dr. Saiman has disclosed that she has served as a principal investigator for Merck & Co., Inc., and received consulting fees from AstraZeneca and MatrixAP.

Dr. LiPuma has disclosed that he has received consulting fees from Johnson and Johnson.

Dr. Miller has disclosed that he has no financial interests or relationships with a commercial entity.

Dr. Muhlebach has disclosed that she has no financial interests or relationships with a commercial entity.

Unlabeled/Unapproved Uses:

The authors have indicated that there will be unlabeled/unapproved references to antiviral agents remdesivir, convalescent plasma, and steroids for the treatment of COVID-19.

Length of activity:

1.0 hour Physicians
1.0 contact hour Nurses

Launch date: December 10, 2020
Expiration date: December 9, 2022

Start Issue